The Fourth Left Atrial Appendage Occlusion Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 4000 participants.

Also called NCT05963698

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 4,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05963698
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05963698. Randomized; single masking; primary purpose treatment. Start 2023-11-30 (actual); primary completion 2029-09-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Fourth Left Atrial Appendage Occlusion Study
Acronym
LAAOS-4
Condition
Stroke, Ischemic
Condition
Systemic Embolism
Intervention (Device)
WATCHMAN device
Lead sponsor
Hamilton Health Sciences Corporation (class: other)
Collaborator
McMaster University (class: other)
Collaborator
Population Health Research Institute (class: other)
Collaborator
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct05963698
Content hash
2dcf7cf31fbf6e52b5148e6568ff5a6842194a4eb5ee9f07b8612241abe391e0